APA (7th ed.) Citation

S, B., AM, O., MJ, B., EP, H., J, H., A, L., . . . JF, L. (2018). Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 29(4), 917. https://doi.org/10.1093/annonc/mdy023

Chicago Style (17th ed.) Citation

S, Banerjee, et al. "Anti-NaPi2b Antibody-drug Conjugate Lifastuzumab Vedotin (DNIB0600A) Compared with Pegylated Liposomal Doxorubicin in Patients with Platinum-resistant Ovarian Cancer in a Randomized, Open-label, Phase II Study." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 4 (2018): 917. https://doi.org/10.1093/annonc/mdy023.

MLA (9th ed.) Citation

S, Banerjee, et al. "Anti-NaPi2b Antibody-drug Conjugate Lifastuzumab Vedotin (DNIB0600A) Compared with Pegylated Liposomal Doxorubicin in Patients with Platinum-resistant Ovarian Cancer in a Randomized, Open-label, Phase II Study." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, no. 4, 2018, p. 917, https://doi.org/10.1093/annonc/mdy023.